Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of ICX-RHY for facial skin imperfections
2006-006443-30Phase 2Completed
- Sponsor
- Intercytex Group
- Start
- Jan 2007
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ICX-RHY-013 in severe cutaneous adverse reactions (SCAR), acne scar and Craniofacial abnormalities, sponsored by Intercytex Group. Primary endpoints: Clinical efficacy analysis and Safety and tolerability analysis. Started Jan 2007; status: completed.
02
Drugs
ICX-RHY-013
03
Conditions
severe cutaneous adverse reactions (SCAR)acne scarCraniofacial abnormalities
Beyond the preview
Go deeper on 2006-006443-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006443-30.